Intensive blood pressure control reduced the composite cardiovascular event rate by 31% (Adjusted HR 0.69) versus usual care over 48 months in hypertensive adults with metabolic dysfunction-associated fatty liver disease.
RCT (n=29,624)
open-label with blinded endpoint assessment
cluster-randomized
Yes
Does intensive blood pressure control targeting <130/80 mmHg reduce major cardiovascular events in hypertensive patients with and without MAFLD?
Intensive blood pressure control targeting <130/80 mmHg significantly reduces the risk of major cardiovascular events in hypertensive patients regardless of MAFLD status, though it increases the risk of hypotension.
Effect estimate: Adjusted HR 0.69 (95% CI 0.61–0.78)
Absolute Event Rate: 19.31% vs 26.99%
p-value: p=<0.001
This study demonstrates that multifaceted intensive BP control at < 130/80 mmHg significantly reduces the risk of cardiovascular disease in patients with MAFLD. These findings provide preliminary evidence for BP management in patients with MAFLD and require confirmation in future prospective clinical trials.
Liu et al. (Tue,) conducted a rct in Adults aged ≥40 years with hypertension with or without metabolic dysfunction-associated fatty liver disease (MAFLD) (n=29,624). Intensive blood pressure control vs. Usual care with standard BP management was evaluated on Composite of stroke, myocardial infarction, heart failure, or cardiovascular death (Adjusted HR 0.69, 95% CI 0.61–0.78, p=<0.001). Intensive blood pressure control reduced the composite cardiovascular event rate by 31% (Adjusted HR 0.69) versus usual care over 48 months in hypertensive adults with metabolic dysfunction-associated fatty liver disease.